Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
Abroad (travel likely)RecruitingPHASE2
Conditions
Endometrial Cancer · ARID1A Gene Mutation · Recurrent Endometrial Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Study coordinator (Panagiotis A Konstantinopoulos, MD, PhD) · Panagiotis_Konstantinopoulos@dfci.harvard.edu · 617-632-5269Contact: Principal Investigator (Panagiotis A Konstantinopoulos, MD, PhD)Brigham and Women's Hospital, Boston, Massachusetts, United States
Contact: Study coordinator (Panagiotis Konstantinopoulos, MD, PhD) · Panagiotis_Konstantinopoulos@dfci.harvard.edu · 617-632-5269Contact: Principal Investigator (Panagiotis Konstantinopoulos, MD, PhD)
Study leads
Panagiotis Konstantinopoulos, MD, PhD
Principal Investigator
Dana-Farber Cancer Institute